Thus, despite in vitro findings of Nef-induced BCL2 upregulation, in vivo HAL tumors may preferentially activate alternative survival pathways such as LMP1-driven NF-κB/PI3K/AKT signaling and MYC amplification, reducing dependency on BCL2 for tumor survival. The gene discussed is MYC; the disease is neoplasm.